NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage

Oral presentation will highlight previously reported data demonstrating early stabilization or impro

NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing n

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stag

Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript

U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostic

Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace

BlackRock Inc. acquired a new stake in Lexeo Therapeutics, Inc. (NASDAQ: LXEO) in the undefined quar

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stag

Avoro Capital Advisors LLC purchased a new stake in Lexeo Therapeutics, Inc. (NASDAQ: LXEO) in the u

Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.30) per share which missed the ana

Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerat

RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical tria

U.S. stock futures mixed, Dow futures up 100 pts. Fermi Inc (FRMI) shares down 20.4% in pre-market a

Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements

JP Morgan analyst Tessa Romero maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and l

Lexeo Therapeutics is a clinical-stage gene therapy company focused on inherited cardiac diseases. T

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript

Lexeo Therapeutics Inc. (NASDAQ:LXEO) stock rose Monday as the company announced a regulatory update

Lexeo Therapeutics stock jumps as LX2006 pivotal trial moves forward, with SUNRISE-FA 2 enrollment s

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, incl

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, incl

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awai

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical sta

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.